

[Flagship launches clinical diagnostics service](#)

written by CAP TODAY

August 19, 2020

August 2020—Flagship Biosciences launched a clinical diagnostics immuno-oncology service, TissueInsight, which provides CLIA-reportable PD-L1 results along with data about the tumor microenvironment, including information on tumor infiltrating lymphocytes and macrophages.

“Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” Trevor Johnson, Flagship CEO, said in a statement. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time, or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.”

[Flagship Biosciences](#), 303-325-5894



©2026 CAP TODAY, all rights reserved.